Genfit Restructuring Cuts Staff by 40%, Creates Two New Subsidiaries
Genfit is halting all work on its lead drug in the fatty liver disorder nonalcoholic steatohepatitis (NASH) and implementing a corporate restructuring that will cut 40 percent of its staff, splitting the remaining workforce into two distinct business units. The announcement after the market close on Wednesday follows the May failure of the drug, elafibrinor, […]